Skip to main content
    S

    Sunshine Biopharma Inc (SBFM)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $2.54
    -0.06 (-2.31%)

    Market Cap: $2.22M

    Last updated: Nov 17, 2026 at 4:37 PM ET

    Sunshine Biopharma Inc (SBFM) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Sunshine Biopharma (SBFM) has a market cap of $2.22M. It kept -17.45% of revenue as net income over the last 12 months.

    Total Valuation

    Market Cap$2.22M
    Latest price (Nov 17, 2026)$2.54

    Key Dates

    The next earnings report is expected on Apr 1, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateApr 1, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 82.77% in the quarter ended Sep 30, 2026.

    Shares Outstanding235.31K
    Shares Change (QoQ)-82.77%

    Price Statistics

    The stock is down 99.22% over 52 weeks and trades 72.51% below its 50-day average.

    Beta (1Y)0.74
    52-Week Change-99.22%
    1-Month Change-47.48%
    3-Month Change-89.15%
    6-Month Change-97.11%
    5-Year Change-99.99%
    10-Year Change-99.99%
    Total Return (1Y)-99.22%
    Total Return (3Y CAGR)-97.11%
    Total Return (5Y CAGR)-84.05%
    Return vs SPY (1Y)-110.71%
    Max Drawdown (1Y)-99.17%
    Max Drawdown (3Y)-100.00%
    Sharpe Ratio (1Y)-2.96
    Correlation with SPY (1Y)0.06
    50-Day Average$9.24
    200-Day Average$94.32
    52-Week Range$2.53 to $464.00
    RSI (14 Days)27.9
    Average Volume (20 Days)389.83K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 6.47x current liabilities.

    Current Ratio6.47x
    Quick Ratio4.03x

    Returns and Efficiency

    Return on equity is -21.56% and return on assets is -18.23% over the last 12 months.

    Return on Equity (ROE)-21.56%
    Return on Assets (ROA)-18.23%
    ROIC (5Y Average)-27.06%
    Asset Turnover1.08x
    Inventory Turnover2.07x
    Receivables Turnover8.92x
    Cash Conversion Cycle149 days

    Scores

    SBFM has an Altman Z-Score of -1.82, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score-1.82
    Altman Z ZoneDistress
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $35.37M over the last 12 months is down 5.23% from the 12 months before.

    Revenue$35.37M
    Revenue Growth (YoY)-5.23%
    Gross Profit$10.74M
    Operating Income-$6.09M
    Pretax Income-$5.83M
    Net Income-$6.17M
    Reported EPS (TTM)-$9.31

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 84.58% of the $33.86M in total assets.

    Cash and Equivalents$14.62M
    Working Capital$26.21M
    Shareholder Equity$28.64M
    Book Value Per Share$121.65
    Tangible Book Value$26.74M
    Tangible Book Per Share$113.60
    Total Assets$33.86M
    Total Liabilities$5.22M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $21.22K of capital spending, operating cash flow left -$5.36M of free cash flow.

    Operating Cash Flow-$5.33M
    Capital Expenditures$21.22K
    Free Cash Flow-$5.36M
    FCF Per Share-$7.04
    Depreciation and Amortization$349.58K

    Trailing 12 months through Jun 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -17.21%.

    Gross Margin30.36%
    Operating Margin-17.21%
    Pretax Margin-16.48%
    Net Margin-17.45%
    Gross Margin (5Y Average)37.28%

    Growth

    Revenue grew 102.91% a year over 3 years.

    Revenue Growth (3Y CAGR)+102.91%
    Revenue Growth (5Y CAGR)+247.73%

    Revenue and profit by year

    Dividends and Yields

    SBFM does not pay a dividend. Its free cash flow yield is -895.98%.

    FCF Yield-895.98%
    Shareholder Yield0.00%

    Stock Splits

    The last split was a 1-for-20 reverse split on Oct 26, 2026.

    Last Split DateOct 26, 2026
    Split TypeReverse split
    Split Ratio1:20

    Analyst Forecast

    Consensus estimates put revenue growth at 11.33% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+11.33%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About SBFM

    What is SBFM's market cap?

    Sunshine Biopharma has a market cap of $2.22M.

    How many shares of SBFM are outstanding?

    Sunshine Biopharma has 235.31K shares outstanding.

    Does SBFM pay a dividend?

    No. Sunshine Biopharma does not pay a dividend.